UnzuC., SampedroA., MauleónI., et al. (2010). Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria. J. Hepatol., 52, 417–424.
2.
Gonzalez-AseguinolazaG., and PrietoJ. (2011). Gene therapy of liver diseases: a 2011 perspective. Clin. Res. Hepatol. Gastroenterol., 35, 699–708.
3.
PañedaA., CollantesM., BeattieS.G., et al. (2011). Adeno-associated virus liver transduction efficiency measured by in vivo [18F]FHBG positron emission tomography imaging in rodents and nonhuman primates. Hum. Gene Ther., 22, 999–1009.
4.
UnzuC., SampedroA., MauleónI., et al. (2011). Sustained enzymatic correction by rAAV-mediated liver gene therapy protects against induced motor neuropathy in acute porphyria mice. Mol. Ther., 19, 243–250.
5.
CarpentierA.C., FrischF., LabbéS.M., et al. (2012). Effect of alipogene tiparvovec (AAV1-LPL(S447×)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J. Clin. Endocrinol. Metab., 97, 1635–1644.
6.
UnzuC., Hervás-StubbsS., SampedroA., et al. (2012). Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates. J. Transl. Med., 10, 122.
7.
UnzuC., SampedroA., SardhE., et al. (2012). Renal failure affects the enzymatic activities of the three first steps in hepatic heme biosynthesis in the acute intermittent porphyria mouse. PLoS One, 7, e32978.
8.
ElderG., HarperP., BadmintonM., et al. (2013). The incidence of inherited porphyrias in Europe. J. Inherit. Metab. Dis., 36, 849–857.
9.
KaeppelC., BeattieS.G., FronzaR., et al. (2013). A largely random AAV integration profile after LPLD gene therapy. Nat. Med., 19, 889–891.
10.
PañedaM.A., Lopez-FrancoE., KaeppelC., et al. (2013). Safety and liver transduction efficacy of rAAV5-cohPBGD in non-human primates: a potential therapy for acute intermitent porphyria. Hum. Gene Ther., 24, 1007–1017.
11.
SalmonF., GrosiosK., and PetryH. (2013). Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera®). Expert Rev. Clin. Pharmacol., 7, 53–65.
12.
SardhE., WahlinS., BjörnstedtM., et al. (2013). High risk of primary liver cancer in a cohort of 179 patients with acute hepatic porphyria. J. Inherit. Metab. Dis., 36, 1063–1071.
13.
UnzuC., SampedroA., MauleónI., et al. (2013). Helper-dependent adenoviral liver gene therapy protects against induced attacks and corrects protein folding stress in acute intermittent porphyria mice. Hum. Mol. Genet., 22, 2929–2940.
14.
YinZ., WahlinS., EllisE.C., et al. (2013). Hepatocyte transplantation ameliorates the metabolic abnormality in a mouse model of acute intermittent porphyria. Cell Transplant. [Epub ahead of print]
